




Edition: BP 2025 (Ph. Eur. 11.6 update)

Phenindione

[General Notices](#)



$C_{15}H_{10}O_2$ 222.2 83-12-5

Action and use

Oral anticoagulant (indanedione).

Preparation

[Phenindione Tablets](#)

DEFINITION

Phenindione is 2-phenylindane-1,3-dione. It contains not less than 98.0% and not more than 102.0% of $C_{15}H_{10}O_2$, calculated with reference to the dried substance.

CHARACTERISTICS

Soft, white or creamy white crystals.

Very slightly soluble in [water](#); slightly soluble in [ethanol \(96%\)](#) and in [ether](#). Solutions are yellow to red.

IDENTIFICATION

The [infrared absorption spectrum](#), [Appendix II A](#), is concordant with the *reference spectrum* of phenindione ([RS 268](#)).

TESTS

Melting point

148° to 151°, [Appendix V A](#).

Related substances

Carry out the method for [liquid chromatography, Appendix III D](#), using the following solutions prepared immediately before use.

- (1) 0.25% w/v of the substance being examined in [methanol](#).
- (2) Dilute 1 volume of solution (1) to 200 volumes with [methanol](#).
- (3) 0.0005% w/v each of [phenindione BPCRS](#), [phenylacetic acid](#) (impurity 3), [benzalphthalide](#) (impurity 4) and [phthalic acid](#) (impurity 5) in [methanol](#).
- (4) Dilute 1 volume of solution (2) to 10 volumes of [methanol](#).

CHROMATOGRAPHIC CONDITIONS

- (a) Use a stainless steel column (10 cm × 4.6 mm) packed with [end-capped octadecylsilyl silica gel for chromatography](#) (3.5 µm) (X-bridge shield C18 is suitable).
- (b) Use gradient elution and the mobile phase described below.
- (c) Use a flow rate of 1.5 mL per minute.
- (d) Use a column temperature of 30°.
- (e) Use a chilled auto-sampler temperature of 4°.
- (f) Use a detection wavelength of 220 nm.
- (g) Inject 10 µL of each solution.

MOBILE PHASE

Mobile phase A 10 volumes [acetonitrile](#), 10 volumes of a 1.36% w/v [dipotassium hydrogen phosphate](#) solution previously adjusted to pH 3.0 with [orthophosphoric acid](#), and 80 volumes of [water](#).

Mobile phase B 10 volumes [water](#) and 90 volumes [acetonitrile](#).

Time (Minutes)	Mobile phase A (% v/v)	Mobile phase B (% v/v)	Comment
0-0.5	80	20	isocratic
0.5-10	80→50	20→50	linear gradient
10-13	50	50	isocratic
13-21	50→30	50→70	linear gradient
21-22	30→80	70→20	linear gradient
22-25	80	20	re-equilibration

When the chromatograms are recorded under the prescribed conditions, the relative retentions with reference to phenindione (retention time about 7 minutes) are: impurity 5, about 0.2; impurity 3, about 0.4; impurity 1, about 0.6; impurity 4, about 1.8 and impurity 2, about 2.4.

SYSTEM SUITABILITY

The test is not valid unless, in the chromatogram obtained with solution (3) the [resolution](#) between the peaks due to impurity 5 and impurity 3 is at least 4.6.

LIMITS

In the chromatogram obtained with solution (1):

the area of any peak due to impurity 1 or 2 is not greater than 0.6 times the area of the principal peak in the chromatogram obtained with solution (2) (0.3% of each);

the area of any other [secondary peak](#) is not greater than 0.4 times the area of the principal peak in the chromatogram obtained with solution (2) (0.2%);

the sum of the areas of all the [secondary peaks](#) is not greater than 3 times the area of the principal peak in the chromatogram obtained with solution (2) (1.5%).

Disregard any peak with an area less than the area of the principal peak in the chromatogram obtained with solution (4) (0.05%).

[Loss on drying](#)

When dried at 105° for 2 hours, loses not more than 1.0% of its weight. Use 1 g.

Sulfated ash

Not more than 0.1%, [Appendix IX A](#).

ASSAY

Carry out the method for [liquid chromatography, Appendix III D](#), using the following solutions prepared immediately before use.

Solution A 2% v/v [glacial acetic acid](#) in [acetonitrile](#).

- (1) Mix with the aid of ultrasound 25 mg of Phenindione in 20 mL of 0.01M [sodium hydroxide](#) and add 50 mL of solution A. Dilute to 100 mL with solution A.
- (2) 25 mg of [phenindione BPCRS](#) in 20 mL of 0.01M [sodium hydroxide](#) and 30 mL of solution A. Make up to 100 mL with solution A.
- (3) 5 mg each of [phenindione BPCRS](#) and [phenylacetic acid](#) (impurity 3) in 5 mL of 0.01M [sodium hydroxide](#) and 5 mL of solution A. Make up to 20 mL with solution A.

CHROMATOGRAPHIC CONDITIONS

- (a) Use a stainless steel column (25 cm × 4.6 mm) packed with [end-capped octadecylsilyl silica gel for chromatography](#) (5 µm) (Symmetry C18 is suitable).
- (b) Use isocratic elution and the mobile phase described below.
- (c) Use a flow rate of 1.0 mL per minute.
- (d) Use an ambient column temperature.
- (e) Use an autosampler temperature of 4°.
- (f) Use a detection wavelength of 250 nm.
- (g) Inject 10 µL of each solution.

MOBILE PHASE

40 volumes [acetonitrile](#) and 60 volumes of 0.68 % w/v [potassium dihydrogen phosphate](#) previously adjusted to pH 3.5 with [orthophosphoric acid](#).

SYSTEM SUITABILITY


The test is not valid unless, in the chromatogram obtained with solution (3), the [resolution](#) between the peaks due to impurity 3 and phenindione is at least 6.0.

DETERMINATION OF CONTENT


Calculate the content of C₁₅H₁₀O₂ using the declared content of C₁₅H₁₀O₂ in [phenindione BPCRS](#).

IMPURITIES


The impurities limited by the requirements of this monograph include:




1. 2-hydroxy-2-phenyl-1H-indene-1,3(2H)-dione




2. 2'-diphenyl-1*H*,1'*H*-[2,2'-bi-indene]-1,1',3,3'(2*H*,2'*H*)-tetrone



3. phenylacetic acid



4. 3-benzylidene-2-benzofuran-1(3*H*)-one (benzalphthalide)



5. phthalic acid